Please join MSU and Jake Chung, PharmD and a Senior Director on the Medical Affairs team at Cabaletta Bio. During this session, Jake  will provide a brief overview of the clinical trial process, review key components of the immune system, and describe how CAR T cell therapy works. He will also review the study design and recent phase 1/2 results of the RESET-Myositis clinical trial, which is evaluating the safety and efficacy of rese-cel (CABA-201) in the treatment of myositis.

Jake Chung is a Senior Director on the Medical Affairs team at Cabaletta Bio, which is the company conducting the RESET-Myositis clinical trial. In his role, Jake works with Patient Advocacy Groups to provide education about Cabaletta Bio’s pipeline treatments and to bring patient insights to the Company. He also leads scientific communication activities for Healthcare Providers and works with Professional Societies across the autoimmune field. Jake is a pharmacist by training. He has spent the past 10 years working in the biotech and pharmaceutical industries focusing on rheumatology and neurology disease areas.

MSU ‘Right Now Research’ and the Myositis Clinical Trials Consortium (MCTC) have developed a clear, patient-friendly FAQ brochure on CAR T cell therapy for myositis:

What CAR T cell therapy is and how it works
How T cells are collected, modified and infused
The typical timeline (apheresis, cell manufacturing, chemotherapy pre-conditioning, infusion and monitoring)
Potential complications (CRS, ICANS, LICATS) and how they are managed
Practical aspects of clinical trials: travel, lodging, caregiver role and financial support
Tips directly from patients who have gone through CAR T

Download and share with your family.